By targeting TRIM22 and modulating the JAK2/STAT3 and ERK signaling pathways, Lyc.HCL may offer a promising strategy for the treatment of ESCC and other cancers in which TRIM22 plays a significant role. This evidence concerns the gene STAT3 and esophageal squamous cell carcinoma.